Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Psychedelic Titans

28 Sep 2021

Psychedelic Titans with Maurice Bright of Psilo Academy, Figarelli House Corp. (dba Psilocybin Academy™)

Psychedelic Titans with Maurice Bright of Psilo Academy, Figarelli House Corp....

By Microdose

Psychedelic Groundbreakers

23 Sep 2021

Psychedelic Groundbreakers: Journey Clinical

This week's Psychedelic Groundbreaker is Journey Clinical, a platform that provides services to members in psychotherapy practices....

By Microdose

Press Releases

21 Sep 2021

Eversio Wellness harvests its first legally grown psychoactive mushrooms

Eversio Wellness, a mushroom wellness company, has harvested its first legal flush of psilocybin-producing mushrooms under its Health Canada-issued Controlled Substances Dealer’s Licence....

By Microdose

Psychedelic Titans

21 Sep 2021

Psychedelic Titans with Kathryn Tucker of Emerge Law Group

This week's Psychedelic Titan is Kathryn Tucker, Special Counsel for Emerge Law Group, a boutique law firm....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Psychedelic Groundbreakers

16 Sep 2021

Psychedelic Groundbreakers: Marcus Maria

This week's Psychedelic Groundbreaker is Marcus Maria....

By Microdose

Psychedelic Groundbreakers

9 Sep 2021

Psychedelic Groundbreakers: Doseology Sciences Inc.

This week's Psychedelic Groundbreaker is Doseology Sciences, dedicated to providing access to fungus-derived medicines and products...

By Microdose

Psychedelic Titans

7 Sep 2021

Psychedelic Titans with Steven Mandel, MD of Ketamine Clinics Los Angeles

This week's Psychedelic Titan is Steven Mandel, MD, Founder of Ketamine Clinics Los Angeles, a leading provider of Ketamine Infusion Therapy....

By Microdose

Psychedelic Groundbreakers

2 Sep 2021

Psychedelic Groundbreakers: Osmind

This week's Psychedelic Groundbreaker is Osmind....

By Microdose

Psychedelic Titans

31 Aug 2021

Psychedelic Titans with Erin Cochrane of Gwella

This week's Psychedelic Titan is Erin Cochrane, Co-founder & Director of Product of Gwella....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.